TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score of 74 Tells Investors
On October 01, 2026, TransMedics Group Inc (TMDX) shares fell 5.8%, closing at $78.64. The stock's performance over the past year has been challenging, with a 5
TMDX - TransMedics Group, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$99.75
DETAILS
HIGH:
$122.00
LOW:
$65.00
MEDIAN:
$100.50
CONSENSUS:
$99.75
UPSIDE:
28.10%
Stock News
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026Shareholders are encouraged to contact the
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible for out-of-pocket payment of our legal fees or expenses.
TransMedics Group (NASDAQ:TMDX) Shares Up 4.5% After Insider Buying Activity
TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares shot up 4.5% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492
2 Stocks Down 28% and 34% to Buy and Hold
These companies' sell-offs may have gone too far.
TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ), announces that K
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”).TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or.
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investors
On September 03, 2026, TransMedics Group Inc (TMDX) shares rose 3.2% to a current price of $86.98, which is situated within a 52-week range of $60.11 to $156.00
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.
TransMedics to Present at Upcoming September Investor Conferences
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
NEW YORK, Aug. 29, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
/PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick and Foti, LLC ("KSF"), announces that
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Price Targets
TransMedics initiated with an Overweight at Barclays
$120.00
(was $80.28)
Barclays
TransMedics price target raised to $122 from $120 at Baird
$122.00
(was $80.75)
Robert W. Baird
TransMedics price target lowered to $95 from $124 at Canaccord
$95.00
(was $80.75)
Canaccord Genuity
TransMedics price target lowered to $65 from $80 at Stifel
$65.00
(was $80.75)
Stifel Nicolaus
TransMedics Group (TMDX) PT Lowered to $106 at Needham
$106.00
(was $76.51)
Mike Matson
·
Needham
TransMedics initiated with a Neutral at UBS
$80.00
(was $74.28)
UBS
TransMedics price target lowered to $90 from $100 at Evercore ISI
$90.00
(was $70.77)
Daniel Markowitz
·
Evercore ISI
TransMedics price target raised to $80 from $75 at Stifel
$80.00
(was $73.22)
Stifel Nicolaus
TransMedics price target lowered to $75 from $85 at Stifel
$75.00
(was $68.94)
Thomas Stephan
·
Stifel Nicolaus
TransMedics price target lowered to $142 from $174 at Needham
$142.00
(was $73.84)
Needham
TransMedics price target lowered to $124 from $152 at Canaccord
$124.00
(was $94.93)
William Plovanic
·
Canaccord Genuity
TransMedics price target lowered to $120 from $160 at Piper Sandler
$120.00
(was $94.93)
Piper Sandler
TransMedics price target lowered to $85 from $130 at Stifel
$85.00
(was $94.93)
Thomas Stephan
·
Stifel Nicolaus
TransMedics price target lowered to $140 from $157 at Baird
$140.00
(was $94.93)
David Rescott
·
Robert W. Baird
TransMedics price target raised to $130 from $115 at Stifel
$130.00
(was $134.77)
Stifel Nicolaus
TransMedics price target raised to $148 from $147 at Canaccord
$148.00
(was $125.04)
Canaccord Genuity
TransMedics price target raised to $166 from $148 at Needham
$166.00
(was $136.51)
Needham
TransMedics price target raised to $135 from $123 at Morgan Stanley
$135.00
(was $150.42)
Morgan Stanley
TransMedics price target lowered to $140 from $145 at Piper Sandler
$140.00
(was $134.32)
Matt O'Brien
·
Piper Sandler
TransMedics Group (TMDX) PT Raised to $147 at Canaccord Genuity
$147.00
(was $134.32)
Jason Mills
·
Canaccord Genuity